Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.
De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation.
Scharrer
I
I
Center of Internal Medicine, University Hospital,. Frankfurt, Germany Baxter Hyland Immuno, Vienna, Austria. scharrer@em.uni-frankfurt.de
Ehrlich
H J
HJ
D000906:Antibodies / Q000097:blood; D005169:Factor VIII / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use
D000906:Antibodies; D011994:Recombinant Proteins; D005169:Factor VIII